Grosser T, Ricciotti E, Fitzgerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 2017;38:733-48. [Ref.ID 101990]

Gedeborg R, Svennblad B, Holm L, Sjögren H, Bardage C, Personne M, Sjöberg G, Feltelius N, Zethelius B. Increased availability of paracetamol in Sweden and incidence of paracetamol poisoning: using laboratory data to increase validity of a population-based registry study. Pharmacoepidemiol Drug Saf 2017;26:518-27. [Ref.ID 101958]

Anónimo. Beta blockers and the risk of CV events in type 2 diabetes. Diabetes in Control 2017:29 de julio. [Ref.ID 101936]

Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909. [Ref.ID 101568]

Grosser T. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2017;376:1389-90. [Ref.ID 101526]

Biffi A, Scotti L, Corrao G. Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies. Eur J Clin Pharmacol 2017;73:487-97. [Ref.ID 101517]

Prada-Ramallal G, Takkouche B, Figueiras A. Diverging conclusions from the same meta-analysis in drug safety: source of data (primary versus secondary) takes a toll. Drug Saf 2017;40:351-8. [Ref.ID 101501]

Sondergaard KB, Weeke P, Wissenberg M, Olsen A-MS, Fosbol EL, Lippert FK, Torp-Pedersen C, Gislason GH, Folke F. Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case–time–control study. Eur Heart J 2017;3:100-7. [Ref.ID 101478]

Pan Y, Hu C, Chen PH, Gu YH, Qiao QY, Pan LH, Zhou DC, Gu HF, Fu SK, Jin HM. Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2017;73:267-78. [Ref.ID 101466]

Anónimo. Mirabégron: fibrillations auriculaires. Prescrire 2017;37:25. [Ref.ID 101365]

Felson DT. Safety of nonsteroidal antiinflammatory drugs.. N Engl J Med 2016;373:2595-6. [Ref.ID 101348]

Anónimo. Celecoxib safety revisited. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:159. [Ref.ID 101041]

Anónimo. Anticonceptivos hormonales: selección adecuada. Boletín Terapéutico Andaluz 2016;31:1-10. [Ref.ID 101040]

Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckeman B, Berger MF, Bao W, Lincoff AM, for the PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;373:2519-29. [Ref.ID 101038]

Martinez C, Suissa S, McGill J, Rietbrock S, Katholing A, Freedman B, Cohen AT, Handelsman DJ. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ 2016;355:i5968. [Ref.ID 101016]

Anónimo. FDA adds warning of abuse potential for medications treating low testosterone. DIA Daily 2016:1. [Ref.ID 100855]

Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol 2016;82:957-64. [Ref.ID 100827]

Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, on behalf of the Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857. [Ref.ID 100756]

Gislason GH, Torp-Pedersen C. NSAIDs and the failing heart. BMJ 2016;354:i5163. [Ref.ID 100755]

Hemkens LG, Ewald H, Briel M. Colchicine and prevention of cardiovascular events. JAMA 2016;316:1106-007. [Ref.ID 100745]